ArticleJournal of neuro-oncology2010
Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.
Article in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 59 citations in OpenAlex.
- The Role of Splicing Machinery as a Promising Potential Therapeutic Target for Pituitary Neuroendocrine Tumors (PitNETs).Cancers · 2026Review
- circOMA1 delivered by exosomes regulates DRD2‑mediated prolactinoma resistance.International journal of molecular medicine · 2026Article
- Immunohistochemical Comparison of Dopamine-2 Receptor Expression in Resistant and Non-Resistant Prolactinomas.Journal of clinical medicine · 2025Article
- DRD2 expression based onEndocrine · 2023Article
- Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.Journal of medical case reports · 2023Review
- Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells.Cancers · 2022Review
- ACT001 inhibits pituitary tumor growth by inducing autophagic cell death via MEK4/MAPK pathway.Acta pharmacologica Sinica · 2022Article
- Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?Endocrine oncology (Bristol, England) · 2022Review
- Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.Nature reviews. Endocrinology · 2021Review
- Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.Journal of feline medicine and surgery · 2021Article
- Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.Frontiers in endocrinology · 2021Review
- Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.Frontiers in endocrinology · 2021Article
- Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.Acta neuropathologica communications · 2020Article
- The Genomic Landscape of Sporadic Prolactinomas.Endocrine pathology · 2019Article
- Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women.The Journal of international medical research · 2019Article
- The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas.Frontiers in endocrinology · 2018Review
- Dopamine Agonists for Pituitary Adenomas.Frontiers in endocrinology · 2018Review
- Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases.Frontiers in endocrinology · 2018Article
- Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.Autophagy · 2017Article
- Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive prolactinomas are more likely to be resistant to drug therapy but the mechanism of this is still unknown. The objective of this study was to analyze the different expression of ERmRNA and D2RmRNA isoforms in prolactinomas responsive and resistant to dopamine agonist (DA), and to discuss the correlation of such gene expression with tumor biological behavior. A prospective study of 20 consecutive patients who harbored prolactinomas was designed. Patients were classified as responsive (14 cases) or resistant (six cases) according to their clinical and biochemical response to bromocriptine. Tumor tissue samples were examined by means of QRT-PCR analysis. Median D2SmRNA expression in responsive patients was about 2.5-fold that in resistant ones (13.5 +/- 10.4 and 5.4 +/- 2.4, respectively, P = 0.09). No significant difference was found between D2LmRNA expression levels (P = 0.77). However, there was a significant difference between D2S/D2LmRNA ratios for responsive and resistant tumors (P = 0.012). A significant difference was not found between these two groups in levels of ERalphamRNA and ERbetamRNA expression (P = 0.20 and 0.06, respectively). D2SmRNA expression was significantly different for invasive and noninvasive tumors (6.2 +/- 3.6 vs. 17.0 +/- 11.2, respectively, P = 0.02). The D2S/D2L ratio is related to the responsiveness of prolactinomas to DA medication, in which D2SmRNA plays an important role. Lower expression of D2SmRNA in invasive tumor patients suggests that invasive prolactinomas may be more likely to be resistant to DA medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.